Candel Therapeutics (CADL) Return on Sales: 2021-2023
Historic Return on Sales for Candel Therapeutics (CADL) over the last 3 years, with Dec 2023 value amounting to -12.99%.
- Candel Therapeutics' Return on Sales rose 26888.00% to -12.99% in Q4 2023 from the same period last year, while for Dec 2023 it was -12.99%, marking a year-over-year increase of 26888.00%. This contributed to the annual value of -14.45% for FY2024, which is 146.00% down from last year.
- Per Candel Therapeutics' latest filing, its Return on Sales stood at -12.99% for Q4 2023, which was down 167.86% from 19.15% recorded in Q3 2023.
- Candel Therapeutics' Return on Sales' 5-year high stood at 68.45% during Q1 2023, with a 5-year trough of -281.87% in Q4 2022.
- For the 3-year period, Candel Therapeutics' Return on Sales averaged around -137.91%, with its median value being -172.88% (2021).
- Per our database at Business Quant, Candel Therapeutics' Return on Sales plummeted by 12,133bps in 2022 and then surged by 31,257bps in 2023.
- Candel Therapeutics' Return on Sales (Quarterly) stood at -207.90% in 2021, then slumped by 7,398bps to -281.87% in 2022, then skyrocketed by 26,888bps to -12.99% in 2023.
- Its last three reported values are -12.99% in Q4 2023, 19.15% for Q3 2023, and 30.42% during Q2 2023.